INCLINE VILLAGE, Nev., May 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences:

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Eleventh Annual JMP Securities Research ConferenceTuesday, May 15, 20129:00 a.m. PDTSan Francisco, CA

Goldman Sachs 33rd Annual Global Healthcare Conference Thursday, June 7, 20128:00 a.m. PDTRancho Palos Verdes, CA

These presentations will be available to interested parties through live and archived audio webcasts. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the events to allow for any software download that may be necessary. The archived webcasts will be available for seven days following each presentation.

About PDL BioPharma PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.

For further information: John McLaughlin, PDL BioPharma, Inc., +1-775-832-8500, john.mclaughlin@pdl.com; Jennifer Williams, Cook Williams Communications, Inc., +1-360-668-3701, jennifer@cwcomm.org